Nanovery is at the forefront of biotechnology, specializing in the development of DNA nanorobots for RNA therapeutic analysis and biomarker quantification. The company serves biotech researchers and pharmaceutical companies, providing them with cutting-edge tools to enhance research precision and streamline testing protocols. Operating in the biotechnology and pharmaceutical markets, Nanovery's business model revolves around the commercialization of its proprietary NAN technology. This technology is enzyme-free and relies on nucleic acid hybridization and strand displacement reactions, making it highly effective for detecting antisense oligonucleotides (ASOs) in pharmacokinetic (PK) assays. Nanovery generates revenue through the sale of its nanorobotic solutions and related services, ensuring its partners remain at the forefront of innovation. The company fosters a diverse and self-motivated team, always on the lookout for outstanding talent to drive further advancements in biotech research.

Keywords: DNA nanorobots, RNA analysis, biomarker quantification, biotechnology, pharmacokinetics, antisense oligonucleotides, enzyme-free technology, nucleic acid hybridization, strand displacement, biotech research.